In this short video we discuss:
• Progress being made in IMU’s gastric and breast cancer immunotherapies 
• Early indications for the treatments and the size of the patient market 
• The commercialisation process and timeline associated with the treatments gaining regulatory approval
• IMU’s expectation around the next trial outcome and funding  
Click below to view video

To view more Executive Series interviews, visit: